A number of other equities analysts also recently commented on the company. Maxim Group restated a buy rating and issued a $10.00 price objective on shares of BIOLINERX LTD/S in a report on Monday, July 22nd. Zacks Investment Research downgraded BIOLINERX LTD/S from a buy rating to a hold rating in a report on Tuesday, July 16th. Finally, HC Wainwright set a $3.00 price objective on BIOLINERX LTD/S and gave the stock a buy rating in a report on Tuesday, May 14th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $4.13.
NASDAQ:BLRX traded down $0.09 during mid-day trading on Thursday, reaching $3.86. The stock had a trading volume of 16,872 shares, compared to its average volume of 71,639. The company has a 50 day moving average of $1.73. BIOLINERX LTD/S has a fifty-two week low of $3.47 and a fifty-two week high of $27.60. The company has a market cap of $29.69 million, a PE ratio of -1.23 and a beta of 1.48. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.12 and a current ratio of 5.12.
Hedge funds have recently made changes to their positions in the business. Deutsche Bank AG acquired a new position in BIOLINERX LTD/S during the fourth quarter valued at approximately $26,000. NEXT Financial Group Inc grew its holdings in BIOLINERX LTD/S by 82.5% during the second quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 33,000 shares during the last quarter. Finally, Delek Group Ltd. acquired a new position in BIOLINERX LTD/S during the first quarter valued at approximately $92,000.
BIOLINERX LTD/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
See Also: Why Dividend Stocks May Be Right for You
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.